Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 1.00 |
| ▸ | PGR | P06401 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.73 |
| ▸ | AR | P10275 | 2/20 | 0.73 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | IL5 | P05113 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | MMP9 | P14780 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | THPO | P40225 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desonide SCHEMBL3631 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL1649865 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL18600318 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL4295093 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL5481974 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL12235707 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL9848320 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL1650014 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL21570018 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HSD17B10HIF1A | |
| Desonide SCHEMBL20535949 | 0.99 | NR3C1 (0.98) | NR3C1PGRCYP3A4HSD17B10HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023284782-A1 | METHOD FOR SCREENING COMPOUND FOR TREATING OR PREVENTING MHTT-RELATED NEURODEGENERATIVE DISEASES, TARGET PROTEIN, AND COMPOUND | 复旦大学 | 2023-01-19 | — | — | WO | disclosed |
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS | 2014-10-16 | — | — | US | disclosed |
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS | 2014-10-16 | — | — | US | disclosed |
| US-8796248-B2 | Oligomer-corticosteroid conjugates | NEKTAR THERAPEUTICS (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796248-B2 | Oligomer-corticosteroid conjugates | NEKTAR THERAPEUTICS (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009045539-A2 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | SERPINA6, NR3C2, NR3C1 | NR3C1 3/4885PGR 1161/4885CYP3A4 331/4885 |
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | SERPINA6, NR3C1, NR3C2 | NR3C1 2/4885PGR 1122/4885CYP3A4 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.